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Abstract: As effective communication is a key ingredient for the provision of quality healthcare
services, this study aimed to explore the communication experiences in the remote monitoring of
older adults with a pacemaker. The study was based on a non-masked randomized observational
design. The Healthcare Communication Questionnaire and in-depth interviews were conducted for
data collection. A total of 49 patients participated in the study. The study findings reveal overall
positive communication experiences by pacemaker users in remote monitoring with no significant
differences from users in hospital monitoring. The remote option is perceived as safe and convenient,
and communicating with the clinicians from home is considered comfortable and confidential.
The study provides insights into the content of communication experiences in telehealth and practical
implications in healthcare contexts. In a world that increasingly relies on remote communication, it is
crucial to match technologies to patient needs and assess communication with patients. This will
ensure the success of new models of care and establish appropriate criteria for the use of telehealth
services. These criteria are all relevant in the implementation of health technology in the future as a
part of effective patient-centered care.
Keywords: pacemaker follow-up; remote monitoring; hospital monitoring; healthcare communication;
cardiovascular diseases
1. Introduction
Cardiovascular diseases (CVDs) are a leading cause of morbidity and the most common cause
of mortality in Europe, leading to almost twice as many deaths as cancer [1]. Among CVDs,
myocardial infarction is considered as one of the top five most prevalent specific causes of death [2].
Pacemakers (PMs) are common implantable medical devices (IMDs) that are surgically placed
inside a patient’s body [3]. It is estimated that each year, 1.25 million permanent pacemakers are
implanted worldwide, and approximately 500,000 were implanted in patients in Europe in 2016 [4].
Indications have broadened from originally only atrioventricular block to also include sinus node
disease and other rhythm abnormalities, causing a continuous growth in the clinical use of PMs [5].
Pacemakers are devices that help in monitoring abnormal heart rhythms and regulate heartbeats,
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and they are most commonly implanted in the chest region [6,7]. According to clinical guidelines,
patients with an implanted PM need to be followed up every 3–12 months [8,9]. Remote follow-up
services are considered a cost-effective option because of an increasing number of patients attending
cardiology services [10]. Remote healthcare services provide several advantages such as increasing
system sustainability, improving demand management, reducing hospital stays, decreasing the number
of health consultations and journeys, improving communication among clinicians and the better access
of users to healthcare services [11,12].
In the Norwegian Coordination Reform for the healthcare sector [13], special attention
was paid to telehealth strategies. The use of telehealth is growing in healthcare services.
Initially, telemonitoring and remote follow-up were used to provide healthcare access to more remote
populations [14]. New telecardiology strategies include remote monitoring (RM) to check system
integrity, alerts on arrhythmic episodes, and potentially replacing in-clinic follow-ups and managing
disease remotely [15]. On comparing patients with RM with those undergoing conventional follow-up
in hospitals, similar frequencies of emergency visits and re-hospitalizations between the two groups
were observed [16]. Additionally, the RM option is a significantly cost-effective alternative [17] and has
a remarkable impact on the informal care given by the relatives and friends of patients with PMs in
terms of their well-being and cost [18].
As remote healthcare services and technology are quickly becoming commonplace for healthcare
organizations across the globe, it is urgent to carry out an associated in-depth study [19]. In relation to
the RM of pacemakers, while many economic evaluations and outcome studies have been conducted,
only a few have focused on the perception of communication by patients living with pacemakers.
Therefore, the present study focused on the communication perception of people living with remotely
monitored pacemakers.
Communication and Monitoring of Pacemakers
Effective communication is key to the provision of quality healthcare services,
and communication between clinicians and patients is fundamental within the framework of
“patient-centeredness” [12,20,21]. Chronic heart failure is a progressive condition characterized
by an uncertain clinical trajectory, with a high risk of morbidity and mortality, that affects over 8% of
older adults, globally [22]. Implantable electronic cardiac devices have revolutionized therapy in
cardiology and are recommended in both national and international guidelines to treat chronic heart
failure secondary to left ventricular systolic dysfunction [23]. The average age of pacemaker recipients
is 75 ± 10 years [24]; therefore, communication efforts should be clearly addressed for the elderly
population. In this case, the understanding and management of illness are challenged by the presence
of multimorbidity, polypharmacy, and frailty. For example, in the United States, older adults with heart
disease, on average, have five other chronic conditions [25] and consume an average of 11 different
medications daily [26], and nearly 76% have described feeling frail [27]. Consequently, the complexity
of this population group challenges health professionals, patients, and informal caregivers to engage
in communication with pacemaker users.
Pacemaker implantation is a very important life event, and therefore, patients may have
different and particular experiences of living with such a device. Thus, prior to remote monitoring
implementation, all involved personnel, including patients, must be well informed and educated about
the RM process and expectations [28]. For example, users should be informed that they are responsible
for keeping their contact information updated, informing about extended travel, maintaining the
function of the transceiver and appropriate landline/cellular communications, and showing up for
in-person assessments when an alert is generated and when asked by the health professionals.
Older adults with heart disease and other chronic conditions require frequent communication
considering their declining conditions [29]. These conversations occur infrequently between patients
and caregivers [30]. Besides, there is a lack of patient-friendly information about telehealth systems,
and patients often rely on third-party information (e.g., on the Internet), which can be inaccurate or
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even wrong [3]. Patient-related barriers are often considered the most important; hence, patients’
perspectives can yield valuable insights for informing clinical approaches for the effective integration
of these new remotely monitored pacemakers.
Earlier research on the elderly population, chronic heart disease, and communication focused
mostly on end-of-life communication and the delivery of bad news without including analyses about
other topics [29,31,32]. To our knowledge, no previous research exists regarding the perceptions
of PM patients about communication during remote monitoring. Increasing our knowledge about
the experience of users’ communication during the remote monitoring of pacemakers could identify
important opportunities for improvement. The perceptions of engaging in communication from the
perspective of older adults with remotely monitored pacemakers remain poorly understood from the
research perspective. To address this gap, this study explored the communication experiences in older
adults with heart conditions, specifically, PM users following remote monitoring. The rationale of this
study was to produce pertinent and translatable knowledge for future opportunities in the context of
the healthcare of these patients and to direct future research.
2. Materials and Methods
This study is a part of a larger project, the NORDLAND study, which has conducting specific
economic evaluations and assessing health-related quality of life, users’ experiences, and the
communication of these new telehealth services since 2014. This project entails collaboration among
chronic heart patients with a pacemaker, their relatives, cardiologists, nurses, psychologists, and health
communication experts.
This study follows a non-masked randomized observational design. The participants, having been
implanted with a pacemaker, were required to be followed up either in the hospital or remotely.
The recruitment took place in Nordland Hospital, Bodø, Norway. This hospital hosts a pacemaker
center that covers 170,000 inhabitants and offers around 80–90 PM implants per year.
The study protocol was as per an earlier study [33]. Every participant had been scheduled for a
pacemaker implant. The inclusion criteria were an age of 18 years or older, the capacity to provide
informed consent and to maneuver the home monitoring system, and a life expectancy > 1 year.
The exclusion criteria were being scheduled for an implantable cardioverter–defibrillator (ICD)
orcardiac resynchronization therapy (CRT), and simultaneous involvement in other studies. All patients
were included consecutively in the study and were followed up for 12 months after the PM implants.
Seventy-six patients were identified in the hospital database, and 50 were invited to participate and
randomized to either remote monitoring (RM, n = 25) or hospital monitoring (HM, n = 25), before being
implanted with the PM. The investigators were not aware of or did not influence the randomization
result prior to inclusion. After this, and due to the explicit nature of the intervention, it was not possible
to blind patients or clinicians to the identity of the group to which they had been randomized.
The patients were implanted with either a single (VVIR) or a dual chamber (DDDR)
pacemaker based on their diagnosis. Further characteristics and descriptions of the devices that were
received by each group of participants are mentioned in detail in a previously published article [16,33].
Data were collected at 6 months and 12 months after surgery. At 6 months, 25 RM patients
and 24 HM patients participated, with each participant answering a set of questions. One HM
patient could not attend due to unavailability. The participants answered an adapted version of
the HCCQ (Health Care Communication Questionnaire) [21], which is listed in Table 1. The HCCQ
aims to measure outpatients’ communication experiences with hospital healthcare professionals.
To further investigate the communication experiences of the RM participants 12 months after the
implants, the 25 participants from the RM group were invited to attend an in-depth interview. In the
total sample, four patients (RM: 2; HM: 2) died from non-cardiovascular causes. In addition, in the RM
group, 11 were unavailable to attend the interview session. Therefore, 12 in-depth interviews were
conducted. A member of the research team was in charge of conducting these interviews by using an
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interview guide including open and closed questions (Table 2). The interview guide was designed to
elicit participants’ communication experiences in relation to the RM of her/his pacemaker.
Table 1. The adapted version of the HCCQ—Health Care Communication Questionnaire [21].
I was asked questions in an aggressive manner
I have been given answers in an aggressive manner
I have been treated with kindness
I have been treated in a rude and hasty manner
The healthcare provider addressed me with a smile
The healthcare provider was able to manage the consultation
The healthcare provider showed respect for my privacy
Table 2. Interview guide.
Why did you find being home-monitored an advantage?
What did you like about talking to the clinicians from home?
What did you dislike about talking to the clinicians from home?
Would you have preferred to have seen the clinicians in person? Why? Why not?
Did you feel comfortable talking to the clinicians from home? Why? Why not?
Did you feel that your session was confidential? Why? Why not?
Have you ever had problems in conducting any data transmission from home? Yes/No
How many times did the doctor call you to the hospital due to findings from data transmission?
Number: _______
After your experience, what kind of monitoring/follow-up would you prefer?
Remote Hospital It does not matter
The above protocol was approved by the Regional Ethics Committee (REK Nord; with the reference
number: 2014/383/REK Nord). The study was developed according to the tenets of the Declaration
of Helsinki. All patients signed corresponding informed consent forms before their enrollment
(patient recruitment and follow-up, from 31 August 2014 to 30 November 2016), and appropriate
measures were taken to ensure data privacy. The trial protocol was registered at ClinicalTrials.gov,
Identifier: NCT02237404.
The statistical analyses were carried out following an earlier published study [18]. To start with,
patient baseline characteristics and potential differences between groups were compared using a
difference-in-means test for continuous variables and a difference-in-proportions test (binomial method)
or the chi-square test (replaced by Fisher’s exact test for cells with n < 5 cases) for qualitative
variables. Next, the results from the questionnaire were presented on a single question based
on a comparison between the two groups, telemonitoring and hospital monitoring, using the
Mann–Whitney U test for ordinal data and the chi-square test for nominal data. The analysis of
the in-depth interviews followed a framework approach, whereby a coding frame was inductively
constructed from the data [34,35]. Analyses were carried out using the SPSS statistical software 24th
edition (SPSS Institute, Inc., Chicago, IL, USA) and NVivo 11th edition for content analysis.
3. Results
The baseline characteristics are presented in Table 3. General information from the six-month
follow-up after the implant is listed in Table 4. There was no significant difference between the RM
and the HM groups with regard to age, gender, pacing indication, and other clinical characteristics.
Differences were only observed in those items that were directly influenced by the type of monitoring,
including “transmissions from patient’s home” and “calls/letters sent to the patients”.
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Table 3. Selected patient baseline characteristics by intervention status.
Groups
Variables All (n = 50) Telemonitoring Hospital Monitoring
p-Value
Age 74.84 (±11.75) 73.68 (±14.22) 76.00 (±8.77) 0.676
Men 26 (52.0) 13 (52.0) 13 (52.0) 1.00
Pacing indication N (%)
Sick sinus syndrome 24 (48.0) 12 (48.0) 12 (48.0)
0.648Atrioventricular block 20 (40.0) 11 (44.0) 9 (36.0)
Chronic AF with bradycardia 6 (12.0) 2 (8.0) 4 (16.0)
Disease manifestations N (%)
Syncope 14 (28.0) 8 (32.0) 6 (24.0)
0.812Dizziness 25 (50.0) 12 (48.0) 13 (52.0)
Dyspnea 11 (22.0) 5 (20.0) 6 (24.0)
Service derived N (%)
Emergency dept. 3 (6.0) 1 (4.0) 2 (8.0)
0.505Cardiology ward 14 (28.0) 5 (20.0) 9 (36.0)
Primary healthcare 4 (8.0) 2 (8.0) 2 (8.0)
Other hospitals 29 (58.0) 17 (68.0) 12 (48.0)
Stimulation N (%)
DDDR 44 (88.0) 23 (92.0) 21 (84.0)
0.334
VVIR 6 (12.0) 2 (8.0) 4 (16.0)
Comorbidities N (%)
Dyslipidemia 27 (54.0) 13 (52.0) 14 (56.0) 0.500
Obesity (BMI > 30) 1 (2.0) 0 (0.0) 1 (4.0) 0.500
Tachyarrhythmia 18 (36.0) 7 (28.0) 11 (44.0) 0.189
Hypertension 32 (64.0) 17 (68.0) 15 (60.0) 0.384
Other comorbidities N (%)
None 18 (36.0) 11 (44.0) 7 (28.0)
0.388Others 10 (20.0) 6 (24.0) 4 (16.0)
Coronary heart diseases 22 (44.0) 8 (32.0) 14 (56.0)
Pharmaceutical treatment N (%)
Antiaggregants 18 (36.0) 8 (32.0) 10 (40.0) 0.384
Anticoagulants 25 (50.0) 10 (40.0) 15 (60.0) 0.129
Antiarrhythmics 18 (36.0) 7 (28.0) 11 (44.0) 0.189
Antihypertensives 32 (64.0) 18 (72.0) 14 (56.0) 0.189
n = 50 (Remote monitoring group: 25; Hospital monitoring group: 25). Values are expressed as means or
proportions. DDDR: Bicameral pacemaker with two electrodes placed in the atrium and in the ventricle;
VVIR: Unicameral pacemaker with an electrode in the ventricle with the ability to modulate the frequency of
stimulation; BMI: Body mass index. Note: this table has been previously published in a previous article [33].
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Table 4. Follow-up general information at six months.
Groups
Variables All (n = 49) Telemonitoring Hospital Monitoring
p-Value
Number of transmissions from hospital N (%)
0 0 (0.0) 0 (0.0) 0 (0.0)
0.261 41 (83.7) 21 (84.0) 20 (83.3)
2 6 (12.2) 2 (8.0) 4 (16.7)
3 2 (4.1) 2 (8.0) 0 (0.0)
Number of transmissions from patient’s home N (%)
0 29 (59.2) 5 (20.0) 24 (100)
<0.0013–5 15 (30.6) 15 (60.0) 0 (0.0)
6–8 5 (10.2) 5 (20.0) 0 (0.0)
Extra transmissions from patient’s home N (%)
0 45 (91.8) 21 (84.0) 24 (100)
0.121 1 (2.0) 1 (4.0) 0 (0.0)
3 3 (6.2) 3 (12.0) 0 (0.0)
Cardiovascular events N (%)
None 46 (93.9) 23 (92.0) 23 (95.8)
0.40PCI 1 (2.0) 1 (4.0) 0 (0.0)
Angina 1 (2.0) 0 (0.0) 1 (4.2)
Lead dislodgement 1 (2.0) 1 (2.0) 0 (0.0)
Calls/letters sent to the patients N (%)
0 27 (55.1) 4 (16.0) 23 (95.8)
<0.0011 21 (42.9) 20 (80.0) 1 (4.2)
3 1 (2.0) 1 (4.0) 0 (0.0)
Changes in medication N (%)
0 33 (67.3) 17 (68.0) 16 (66.7)
0.11
1 7 (14.3) 5 (20.0) 2 (8.3)
2 3 (6.1) 1 (4.0) 2 (8.3)
3 4 (8.2) 0 (0.0) 4 (16.7)
4 2 (4.1) 2 (8.0) 0 (0.0)
Changes in pacemaker’s programming N (%)
0 34 (69.4) 16 (64.0) 18 (75.0)
0.341 13 (26.5) 7 (28.0) 6 (25.0)
2 2 (4.1) 2 (8.0) 0 (0.0)
Number of hospitalizations (related or not to pacemaker’s implant) N (%)
0 30 (61.2) 14 (56.0) 16 (66.7)
0.551 14 (28.6) 7 (28.0) 7 (29.2)
2 4 (8.2) 3 (12.0) 1 (4.2)
5 1 (2.0) 1 (2.0) 0 (0.0)
Number of hospitalization days (related or not to pacemaker’s implant) N (%)
0 30 (61.2) 14 (56.0) 16 (66.7)
0.541–5 12 (24.5) 6 (24.0) 6 (25.1)
6–10 4 (8.1) 2 (8.0) 2 (8.4)
+10 3 (6.0) 3 (12.0) 0 (0.0)
Reasons for hospitalization N (%)
None 30 (61.2) 14 (56.0) 16 (66.7)
0.37
Others 6 (12.3) 3 (12.0) 3 (12.5)
Cancer 1 (2.0) 1 (4.0) 0 (0.0)
Coronary problems 9 (18.4) 4 (16.0) 5 (20.8)
Pacemaker
dysfunction 3 (6.1) 3 (12.0) 0 (0.0)
n = 50 (Remote monitoring group: 25; Hospital monitoring group: 24). Values are expressed as means or proportions.
PCI: Percutaneous coronary intervention. Note: this table has been published in a previous article [33].
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At 6-month follow-up, 24 participants from each group answered the questionnaire about the
results derived from the HCCQ. The overall communication experience with both types of follow-ups
was positive, and there was no significant difference between the remote monitoring and the hospital
monitoring groups (see Table 5).











1 = Not at all;
2 = To a small extent;
3 = To a moderate extent;
4 = To a large extent;
5 = To a very large extent
1 (1, 5) 1 (1, 1) 0.383
Question 2 1 (1, 2) 1 (1, 1) 0.332
Question 3 5 (2, 5) 5 (3, 5) 0.363
Question 4 1 (1, 3) 1 (1, 1) 0.332
Question 5 4 (2, 5) 5 (3, 5) 0.431
Question 6 5 (2, 5) 5 (3, 5) 0.718
Question 7 5 (1, 5) 5 (3, 5) 0.379
* Data presented as median (min., max.).
After 12 months of surgery, the participants from the RM group were invited for an in-depth
interview. In total, 12 participants accepted and attended the interview session, while the remaining
patients declined to participate in the interviews due to unavailability or death. Each interview
lasted approximately 30 min. The participants provided highly productive information that was
processed. Quotes from the participants are also provided (see Table 6). In general, the participants
reported positive experiences about the RM option. Considering the RM advantages, 66% of the
participants (n = 8) perceived this new system as a safe option, as they felt they were being continuously
followed up. Particularly, an additional advantage was reduced visits to the hospital, mainly because
of the traveling time and costs. The participants also indicated positive experiences about talking to
the clinicians from home, importantly, that it was easy and that they felt safe. No participant showed
any dislike of these remote conversations with clinicians. The majority of the participants (n = 9.75%)
did not prefer to meet the clinicians in person. Two patients (16%) mentioned that they would have
preferred to meet the clinicians in person only if their health status decreased or some problems with
the PM occurred. One participant (8%) mentioned his preference to meet the clinicians sometimes
in the hospital for specific questions. All participants felt comfortable about talking to the clinicians
from home, and also felt that the RM system was confidential. One patient (8%) mentioned having
problems when conducting data transmission from home. Finally, considering what system they
would prefer based on previous experience, 58% of the participants (n = 7) preferred the remote
follow-up, 33% participants (n = 4) did not show any particular preference for either RM or HM,
and 8% participants (n = 1) would have preferred a hospital follow-up.
Table 6. Quotes from participants in the remote monitoring group, 12 months after surgery.
“I felt safe with this continuous follow-up”, participant number 1.
“I feel that the session was confidential, I trust in the system”, participant number 16.
“It was comfortable to speak with the clinicians from home because I got the answers I needed”, participant
number 22.
“Talking to the clinicians from home was safe”, participant number 34.
“One of the main advantages for the remote monitoring is that I do not have to travel to the hospital”,
participant number 47.
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4. Discussion
This study explored the communication experiences in PM users through remote monitoring
to produce pertinent and translatable knowledge for future opportunities in healthcare contexts.
To our knowledge, this is the first study to explore the follow-up communication experiences of PM
users living remotely. Our findings revealed (a) overall positive communication experiences in RM
pacemaker users, (b) no differences in the communication experiences between the RM and HM users,
(c) the perception of remote follow-up as a safe and confidential option, and (d) talking to the clinicians
from home is a comfortable option.
Although the patients following remote or in-home follow-ups of pacemaker implants have fewer
scheduled visits to the hospital and consequently less in-office contact with clinicians, our results
reveal an overall positive communication experience. These patients had a scheduled visit to the
hospital after one month of surgery, during which the physician explained the characteristics of the
monitoring that they had been assigned to. Following the international consensus on the monitoring
of cardiovascular implantable electronic devices [36], the RM patients were advised in the beginning
that they would be called only if something went wrong. The RM pacemaker automatically collects
and transmits encrypted health information to the Home Monitoring Service Centre, depending on the
patients’ needs as defined by their physician. Therefore, after one month, no visits were scheduled in
the RM group. These patients were called and referred for an in-office visit only if the received data
detected any device dysfunction or a cardiovascular event.
An important outcome of our study was that the patients with in-home follow-up perceived
similar communication experiences with hospital healthcare professionals to the patients with hospital
follow-up. This is an important finding that is supported by a previous study that compared the two
types of follow-up. However, while in this study, there was no perceived loss of communication,
the earlier study was conducted in another health setting [14]. Different studies suggest that telehealth
providers require high-level communication skills, for example, to compensate for a lack of visual
cues [37–39]. Therefore, we may assume that communication by clinicians met the patients’ needs in
our study. Varma (2016) states that effective communication with patients in remote follow-up should
include a good presentation of the benefits of this healthcare model. Information on the expected
reaction times should be cautiously described to patients, who should also be educated, along with
their caregivers, on how to proceed in emergencies. Furthermore, to maintain effective ongoing
communication with patients, personal knowledge of the clinicians who phone the patient when there
is trouble may significantly strengthen their relationship.
Issues of patient safety in telehealth have been largely unexplored [40]. During the in-depth
interviews conducted with the participants under RM, the majority of the patients perceived this
type of follow-up as a safe, comfortable option and that they would prefer this remote option to the
hospital follow-up. Our findings are well aligned with those of Donelan et al. [14], who observed that
patients under remote follow-up perceived considerable added convenience and saved travel time,
and a majority also recommended it to family and friends. Nevertheless, other authors analyzing
this type of communication suggested the need for the personal contact of these patients with
clinicians because patients with an insertable cardiac monitor experienced the feeling of “not knowing”
or “being uninformed” [41]. In this regard, Kirkegaard et al. [42] argued that telehealth solutions
cannot be a stand-alone option with no presence of the healthcare provider, especially in patients with
long-term conditions. In telehealth services, the absence of visual stimuli provides unique barriers to
communication and increases the risk of misunderstandings and distractions [43]. However, in the case
of the remote follow-up of patients with pacemakers, there is no need for information exchange unless
something goes wrong, although, in this case, personal contact was made. One month after surgery,
patients are advised that in the RM environment, “no news is good news”. Our study may have found
positive communication experiences because personal contact was unnecessary during the follow-up
process and the remote communication experiences were perceived as successful. The sample of patients
with an RM pacemaker considered this type of follow-up as safe and comfortable. However, this should
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be further analyzed in other health settings. For example, in a study on telerehabilitation settings
including patients with heart disease, lymphedema, and chronic pulmonary obstructive disease,
personal contact with clinicians was perceived safer by patients [44]. Furthermore, some other
studies recommend that as these patients are often suffering mentally from depression or anxiety,
clinicians should be aware of significant mental health symptoms that cannot be perceived by the
remote follow-up system [45,46].
Therefore, the authors suggest a balanced remote follow-up system that includes several phone
calls, even when the system has not declared any unusual event. Considering that this group of
patients is specially aged with high comorbidity, there may be queries related to the pacemaker,
especially when they are asymptomatic; thus, this contact is the only mode for knowing about their
health status and confirming their progress. This induces us to reflect on the following Albert Einstein
quote: “The human spirit must prevail over technology”.
We recognize limitations to this work, which need to be considered before making any
interpretation of the results. Measuring a patient’s communication experience includes feedback
biases from intentionally answering the questionnaires to accomplish positive outcomes. Our overall
positive communication experiences could have been influenced by the phenomenon called the
“Hawthorne effect” [47], which states that patients tend to change their behavior when they are targets
of interest and attention, irrespective of the specific nature of an intervention, which could be a
limitation of our results. In such situations, patients may become eager to please their clinicians and
make them feel successful. In addition, some patients wish to participate so that “good” results can
be achieved in the study. Particularly, most data describing communication experiences come from
retrospective approaches using questionnaires, interviews, and focus groups. Such retrospective data
are subject to recall bias. Further research must be carried out using more reliable techniques such as
observation and/or recording to assess skills in communication between clinicians and patients in real
time [48]. Another limitation is that we conducted an open study wherein the clinicians, researchers,
and patients knew the follow-up types. Finally, we would like to mention that the sample included in
the NORDLAND study was small and that further research should consider strengthening this aspect.
In addition, further research could also focus on analyzing the level of health and technology literacy
of pacemaker users, as this could be an important point to consider in the implementation of this new
technology. Nonetheless, we believe that this study presents some significantly strong points because
the NORDLAND study is a randomized study in a field where it is not common to conduct such a
method design. This ensures a major evidence level, a reduced chance of bias due to the random
selection of the groups, and maybe repeatability and comparability with other studies. In a world
that increasingly relies on remote communication, it will be crucial to match technologies to patient
needs and assess communication with patients [49]. This will ensure the success of new models of
care and establish appropriate criteria for the use of telehealth services. These criteria are all relevant
in the implementation of health technology in the future as a part of effective patient-centered care.
Telehealth should aim to improve the quality of health services with a special focus on overcoming
standing barriers to healthcare when attending traditional hospital visits.
5. Conclusions
With the unstoppable implementation of digital contributions to meet the different needs of the
patients, telehealth is expected to be adopted progressively. This study provides some insight into the
content of communication experiences in telehealth and confirms positive communication experiences
in cases of people with pacemakers in remote follow-up. These new health technologies might be a
great complement, especially for the long-term sick population. It is thus critical to continue to develop
strategies to assess and improve the communication experiences of patients. In our study, the patients
reported communication experiences in a specific health setting, that of the remote monitoring of
pacemakers. This study design may also be considered for other settings, as there is a lack of analysis
of communication experiences with other telehealth services.
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